Member Info for mulledwine

Elementis announces completion of its acquisition of Watercryl Quimica Ltda. Elementis plc (ELM.L) ("Elementis"), the FTSE 250 Global Specialty Chemicals Company, is pleased to announce that the acquisition of Watercryl Quimica Ltda., which was announced on 26 June 2012, was completed in Sao Paulo on Friday 28 September 2012.

SP fell from this level in Jan 12 but climbed from it in April 12 - so which way now - it has been here for quite a while - a move is on the cards.

Ivan Dunleavy, Chief Executive said: "We are delighted to have successfully concluded discussions with the Isle of Man Treasury. This agreement is a further example of extending the reach of the Pinewood brand and builds on the Company's successful Pinewood Films initiative to play a bigger role in UK independent film and television production. Pinewood is a key part of the UK's film industry which made an economic contribution to the UK economy of £4.6bn in 2011. "The Company's unique assets in the UK, together with its film financing and strategic international initiatives, mean that it is well placed to cater for the existing and planned global growth in creative content. Demand for stage capacity at Pinewood continues to rise and as a result the Board has approved an additional 45,000 sq ft studio facility, including a new sound stage, at Pinewood Studios. Pinewood is an expanding global brand, allowing access to premium services around the world".

Trading update Film revenues are now largely contracted for the remainder of the financial year. The investment in Pinewood's television facilities was completed on time and within budget and has resulted in further interest in its television offering. Media Park occupancy levels remain high at 96%. On 7 September, Pinewood Films announced a further film investment project, Belle, which began shooting on 24 September 2012. The consultation on the future expansion of Pinewood Studios continues and an outline planning application will be submitted to the local planning authority, South Bucks District Council, in the autumn.

CONT Under the terms of the IOMT Agreement, PFA will receive: an annual management fee; fees on film projects that the IOMT invests in; a proportion of the revenues received from the UK distribution rights for films; and a proportion of the revenue received from the existing library of 97 IOMT funded films as a fee for managing the collection of revenues arising from those films. The IOMT intends to offer a broad range of film investment including equity finance; UK distribution and 'gap' financing. There are no upper or lower limits on its investments and each project will be considered on a case by case basis. On completion of the IOMT Agreement, Steve Christian, the current Chairman of CinemaNX (the previous adviser to the IOMT), together with a core team of four CinemaNX employees will join PFA to provide additional expertise and continuity.

Agreement with the Isle of Man Treasury to advise on film investment opportunities and to undertake UK distribution activities for its £25m fund and trading update Agreement with the Isle of Man Treasury Further to the announcement of 6 June 2012, Pinewood Shepperton plc ("Pinewood" or the "Company"), a leading provider of services to the global film and television industry, today announces that it has signed an agreement (the "IOMT Agreement") with the Isle of Man Treasury ("IOMT") to source and advise on film investment opportunities for the £25 million fund established by the IOMT and to monitor and capitalise on UK distribution rights in films and television programmes funded by the IOMT. The IOMT will be advised by Pinewood Film Advisors Limited ("PFA"), a wholly owned subsidiary of the Company. The initial period of the IOMT Agreement will be five years. The IOMT Agreement is conditional on PFA receiving certain required consents from the Financial Services Authority and Pinewood expects to satisfy such conditions within the next few weeks. A further announcement will be made in this regard in due course. In addition, the Company notes that Goodweather Investment Management Limited (a member of the Peel Group) has agreed to sell 4,891,582 ordinary shares in the capital of Pinewood to IOMT at a price of 250 pence per share. Completion of the sale of these shares is conditional on the IOMT Agreement completing by 31 October 2012. In connection with its proposed acquisition of shares in Pinewood, IOMT has given an undertaking to Pinewood and N+1 Brewin that it will not acquire any other shares in Pinewood until the expiry of the period ending two years after it acquires the shares, subject to certain exceptions including pursuant to a general offer or scheme of arrangement or to maintain an aggregate holding of 9.9% of Pinewood's issued share capital or at any time with N+1 Brewin's consent.

http://www.investegate.co.uk/Article.aspx?id=201210010700085251N

Wetherspoon (J.D.) Sell 24-Sep-12 £23,382.42 John Hutson 4,933 @ 474.00p Wetherspoon (J.D.) Sell 24-Sep-12 £19,836.90 Su Cacioppo 4,185 @ 474.00p

Aegis Group Sell 28-Sep-12 £307,617.61 Nick Priday 130,457 @ 235.80p

Shares of Cambridge-based Vectura rose after it confirmed the Japanese government has approved its Seebri inhalation capsules used in inhaler devices. The shares rose 2p to 86.5p, on news that government clearance will trigger a £2.5m milestone payment for Vectura from its partner Novartis. Whether by coincidence or not, Vectura director Dr Chris Blackwell chose this day to exercise options that entitled him to buy 277,776 ordinary shares at 48.125p a pop. The options were granted through Vectura's enterprise management incentive (EMI) scheme.

In the opinion of Seymour Pierce Electrocomponents’s flat sales growth in the second quarter of 2013 was a decent outturn given tough comps (+8% one year ago) and the global macroeconomic background. In particular, they believe that today’s results showed that Electrocomponents is outperforming the market and its closest peer Premier Farnell. Group gross margin is expected to be 1.2% lower in the first half of 2013 given the increased use of customer discounts, changes in product mix towards lower margin products (e.g: Raspberry Pi) and adverse foreign exchange movements.

In a report issued yesterday analysts at Charles Stanley downgraded their view on shares of contract caterer Compass Group, to hold from buy. Thus, they pointed out how: “Over the last 12 months the Compass Group share price has risen by 30% and is near record highs. “Compass Group will be publishing its FY12 results on 21st November and today, it has issued a trading update for the year ended 30 September 2012. As expected, the Group has delivered a good performance in quarter four and for the year organic revenue growth of about 5.5% is as expected with strong performances in North America and Fast Growing & Emerging regions offsetting a weak performance in Europe & Japan.

GECR Target price 251p The Quarto Group Better Than Expected Interim Results Despite the challenging global economic environment, the Quarto Group announced better than expected interim results, as a continued strong performance from its Book Publishing segment more than compensated a weaker one from its International Co-Division. The group also recently received a written request for a special meeting of shareholders to vote on two resolutions. The resolutions are to remove Laurence Orbach (co-founder, chairman, chief executive officer and largest individual shareholder) as a director of the company; and to elect Tim Chadwick as a director. While we await further news on this, with a significant part of revenues still to come in the second half of the year, we rate the shares as a strong buy.

Singer Capital retained its "buy" stance on The Innovation Group (TIG) with a target price of 23p. The automotive software developer launched two new products, Insurer Rapid Assess and Insurer Gateway, which the broker said will increase efficiency at insurance firms, by reducing the amount of time it takes to assess external car damage. Singer maintained its view that the firm will increase its EBITDA margin to 20% by 2015 and adjusted profit margin to 15%

Panmure Gordon reiterated its "buy" recommendation for Gable Holdings (GAH) with a 38p target price. The broker expects the insurance company to report first half pre-tax profits of 3.7 million pounds, up 43% year-on-year, benefiting from the launch of its first policy in Germany. Panmure noted that the firm has secured a new property liability programme win in France, worth 4.5 million euros (3.6 million pounds) per annum and an after the event programme in UK worth 3 million pounds per year.

Singer Capital maintained its "buy" rating for Cello Group (CLL) with an increased target price of 56p, from 48p. The broker said that the marketing company has seen a recovery in demand for its consumer business, following a difficult first half, with record bookings in August. Meanwhile, Singer noted that the company's health division remained strong. Forecasts for full year earnings put the shares on a prospective multiple of 6.7 times for 2012, falling to 6.2 times in 2013

Panmure Gordon reiterated its "buy" recommendation for Marston's (MARS) with a 130p target price. The pub chain reported like-for-like sales growth in its managed pubs for the 42 weeks ended 31st July and the broker expects this trend to have continued for the remainder of the year. Panmure noted that the firm will complete 25 new pub restaurants during the current financial year, with plans of opening between 20 and 25 per year from now on. Trading on a prospective EV/EBITDAR multiple of 7.9 times and yielding a dividend of 6%, the broker views Marston's as one of the cheapest pub stocks available

Alan Reade, Executive Chairman of TyraTech commented: "We are pleased to have announced within the last few days our Trademark License Agreement with Terminix and the launch in early 2013 of our products at The Home Depot in the U.S., the world's largest home improvement retailer. We believe that this will be a significant catalyst for the future growth of TyraTech, and re-enforces our optimism for the Company's short and medium-term prospects. Other out-licensing and partnering discussions are also progressing well, but in order to help deliver this potential, we believe it would be in shareholders' interests to raise additional financing in the near future, which could be by way of debt or equity."

Financial Highlights: · Cash and cash equivalents of US$2.1 million at 30 June 2012 (US$1.6 million at 30 June 2011 and US$0.9 million at 31 December 2011); · Raised US$3.8 million in capital in February 2012, net of expenses, through the issuance of 52,101,460 common shares; · Total revenues from continuing operations decreased to US$0.4 million (2011: US$5.0 million) as a result of decreased sales to our largest customer; · Gross profit decreased to US$0.3 million (2011: $3.5 million); · Overall operating expenses decreased to US$3.2 million (2011: US$4.1 million); and · Loss increased to US$2.8 million for the first half of 2012 (2011: US$0.5 million net loss). To help maximize the potential value to shareholders that would be captured by successfully concluding ongoing negotiations with commercial partners, to ensure the Company's working capital position, and, potentially, also to fund the increased capital requirements of the business associated with production of leading product lines, the Board believes that the Company should plan to raise additional funding. A number of discussions are taking place and further announcements will be made as appropriate.

Interim Results for the six months ended 30 June 2012 TyraTech, Inc. ("the Company") (AIM: TYR and TYRU), a natural life sciences company that harnesses the power of nature to improve human and animal health using a proprietary, novel technology that is both effective against insects and parasites and safe for people and pets, today announces its interim operating and financial results for the six month period ended 30 June 2012 and other post period operating events. Operational Highlights: · Entered into a Trademark License Agreement with Terminix which licenses the use of the Terminix brand to TyraTech for sales of the Company's insect control products, opening the U.S. consumer market for the Company; · Reached agreement with The Home Depot for the 2013 U.S. launch of the Company's new line of consumer insect control products utilizing the Terminix brand; · Successful development of a floor and surface repellent product resulting in a near-term opportunity to conclude an agreement with a major fast-moving consumer goods ("FMCG") group and medium to longer term discussions with the same party on a prospective global license for household pesticides; · Submission of the Company's regulatory package for a head lice removal kit to the U.S. Food and Drug Administration ("F.D.A.") and the U.K. Medicines and Healthcare products Regulatory Agency ("M.H.R.A."); · Completion of a human clinical study of a natural formulation for head lice showing greater effectiveness than the current synthetic based market leader which the Company believes will form the basis for further products; and · Development of a personal insect repellant and submission of regulatory packages to authorities with expected product launch in the first half of 2013.